Enveric Biosciences IncNASDAQ:ENVB
- LAST PRICE2.6600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.6600/ 10
- Ask / Lots2.9500/ 7
- Open / Previous Close0.0000 / 2.6600
- Day Range---
- 52 Week Range
- Volume5
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | ENVB |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Enveric Biosciences Inc | 5.5M | 0.0x | --- |
Premier Biomedical Inc | 5.5M | -0.3x | --- |
Capstone Holding Corp | 5.8M | -5.6x | --- |
RenovaCare Inc | 5.2M | -0.9x | --- |
First Wave BioPharma Inc | 5.8M | 0.0x | --- |
Virios Therapeutics Inc | 5.9M | -0.2x | --- |
Company Information
Enveric Biosciences, Inc. is an early-development-stage biosciences company. The Company is developing next-generation mental health and oncology treatments using a clinical discovery platform to enable psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. It is developing its product candidates that are focused on cannabinoids derived from non-hemp botanical sources, and synthetic materials containing no tetrahydrocannabinol (THC) in order to comply with United States federal regulations. Its product candidates include EV104, EVM-101, EVM-201, EVM-301, EV102 and EV101. EV104 includes cannabidiol (CBD) and celecoxib conjugate. EVM-101 is a first-generation psychedelic asset, which is a psilocybin oral formulation. EVM-201 is a second-generation psychedelic asset, which is a prodrug of psilocin. EVM-301 is a third-generation psychedelic. EV102 is a cannabinoid cream for topical skin application. EV101 is a cannabinoid plus chemotherapy combination therapy.
Contact Information
- Headquarters
- 4851 Tamiami Trail N, Suite 200NAPLES, FL, United States 34103
- Phone
- 239-302-1707
- Fax
- 732-243-9254
Executives
- Executive Chairman of the Board
- David Johnson
- President, Chief Operating Officer
- Avani Kanubaddi
- Chief Executive Officer, Director
- Joseph Tucker
- Interim Chief Financial Officer
- Robert Dickey
- Chief Medical Officer
- Bob Dagher
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.44 |
EPS | $-72.38 |
Book Value | $34.23 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
